Rivaroxaban: It's Not Time to Cut the Rope, Yet

The warfarin arm of the ROCKET AF trial used a faulty INR device, leading to calls for independent verification of the study. Dr Mandrola agrees but is reassured by the real-world data on rivaroxaban.